Safety of infliximab in inflammatory bowel disease needs to be debated.
de Vries
Hilbert S
HS
Van Oijen
Martijn G H
MG
de Jong
Dirk J
DJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D008875:Middle Aged; D055815:Young Adult
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000069285:Infliximab